Previous reports showed rapid improvement of proteinuria, kidney dysfunction, and hypertension after discontinuation of anti-VEGF therapies.[24,25] In the present study, 2 of 5 patients with ramucirumab-induced nephrotic syndrome maintained partial recovery of kidney function. The gene discussed is VEGFA; the disease is hypertensive disorder.